Skip to main content
. 2022 Jun 1;27(9):740–750. doi: 10.1093/oncolo/oyac082

Table 1.

Descriptive statistics for all variables of interest in patients with stage III CC.

Variable label Level N (%) = 41 707
Facility type Community cancer program 5458 (13.1)
Comprehensive community cancer program 20 541 (49.3)
Academic/research program 9593 (23.0)
Integrated network cancer program 6115 (14.7)
Facility location Northeast 9606 (23.0)
South 13 894 (33.3)
Midwest 11 815 (28.3)
West 6392 (15.3)
Age at diagnosis Mean 79.42
Median 79.00
Minimum 70.00
Maximum 90.00
SD 6.04
Missing 0.00
Sex Male 17 544 (42.1)
Female 24 163 (57.9)
Median income quartiles 2000 <$30 000 5347 (13.2)
$30 000-$34 999 7316 (18.0)
$35 000-$45 999 11 675 (28.7)
≥$46 000 16 305 (40.1)
Missing 1064
Primary site C180-cecum 12 307 (29.5)
C182-ascending colon 10 545 (25.3)
C183-hepatic flexure of colon 2156 (5.2)
C184-transverse colon 4264 (10.2)
C185-splenic flexure of the colon 1317 (3.2)
C186-descending colon 2124 (5.1)
C187-sigmoid colon 8242 (19.8)
C188-overlapping lesion of colon 752 (1.8)
Grade Well differentiated, differentiated, NOS 2500 (6.0)
Moderately differentiated, moderately well-differentiated, and intermediate differentiation 25 508 (61.2)
Poorly differentiated 11 924 (28.6)
Undifferentiated, anaplastic 1775 (4.3)
Risk Low risk 21 485 (51.5)
High risk 20 222 (48.5)
Race White 36 219 (87.4)
Black 3687 (8.9)
Other 1532 (3.7)
Missing 269
Hispanic ethnicity No 37 705 (95.8)
Yes 1663 (4.2)
Missing 2339
Insurance type Not insured 215 (0.5)
Private insurance 3989 (9.7)
Government insurance 36 963 (89.8)
Missing 540
Year of diagnosis 2004-2006 8507 (20.4)
2007-2009 7216 (17.3)
2010-2012 12 614 (30.2)
2013-2015 13 370 (32.1)
Surgical margins Negative 37 574 (90.9)
Positive 3764 (9.1)
Missing 369
Charlson-Deyo scores 0 25 728 (61.7)
1 10 774 (25.8)
≥2 5205 (12.5)
Tumor size ≤2 cm 1660 (4.1)
2-4 cm 14 007 (34.3)
>4 cm 25 201 (61.7)
Missing 839
Chemotherapy type No chemotherapy 21 450 (51.4)
Single-agent chemotherapy (SAC) 7334 (17.6)
Multi-agent chemotherapy (MAC) 12 923 (31.0)